Development of such an inhibitor, if truly HDAC6-specific and fitting the patient tolerability profile seen with current HDAC6 deacetylase inhibitors, would provide a strategy to sensitize NSCLC tumors to conventional DNA damaging agents. Here, HDAC6 is linked to non-small cell lung carcinoma.